IMPACT OF NLEM-2015 ON PHARMACEUTICAL INDUSTRY

PRESENTED BY:AMAN DUBE (QA-04)RIDDHI DESAI(QA-03)RUQAIYA VASI (QA-17)IAN FERNANDIS (QA-20)KANJANI SHAH(QA-15)

NLEM 2015

The health ministry has revised its National List of Essential

Medicines (NLEM) to include 376 drugs in the new NLEM 2015 list.

While a total of 106 medicines have been added, 70 medicines have been deleted to finalize the

new list.

VALUE LOST ON INCREMENTAL PRICES CAPPED AS PER REVISED NLEM LIST

VOLUME GROWTH TRENDS

PRICING GROWTH TRENDS

EFFECT ON THERAPEUTIC CATEGORIES

CIPLA SALES GROWTH TRENDS

Source: IMS

124%

217%

322%

419%

518%

ABACAVIR

12345

1 = 20112 = 20123 =20134 = 20145 = 2015

Source : IMS

112%

217%

320%

425%

527%

TENOFOVIR

12345

REVENUE CONTRIBUTION OF MOLECULES OF CIPLA

Source: IMS

Source : IMS

ANTICANCER DRUGS

INCLUDED IN NLEM 2015

Comparison of Pfizer growth with other MNCs

IMPACT OF NLEM 2015 ON PFIZER

Cardiac segment

Anti-infective segment Anti-infective segmentMolecule wise sales

Anti- diabetic segment

ACUTE/ CHRONIC BREAK UP

PRE-NLEM: Rise the price to harvest maximum profit.

POST-NLEM: If increase in volume will maintain the profit, then promotion should not be stopped.

Keep the margin same for distributor and retailer to maintain good relationship with them.

Start focusing on Semi regulated countries.

Product Line extension.

STRATERGY FOR PFIZER AND CIPLA

MNC

Thank You